• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CSF3R作为胶质瘤潜在的预后生物标志物和免疫治疗靶点。

CSF3R as a potential prognostic biomarker and immunotherapy target in glioma.

作者信息

Huang Minglei, Zhang Longze, Wu Yan, Zhou Xue, Wang Yanyang, Zhang Jidong, Liu Ye, He Zhixu, Wang Xianyao

机构信息

Zunyi Medical University, China.

出版信息

Cent Eur J Immunol. 2024;49(2):155-168. doi: 10.5114/ceji.2024.140651. Epub 2024 Jun 21.

DOI:10.5114/ceji.2024.140651
PMID:39381559
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11457564/
Abstract

INTRODUCTION

Gliomas are the most common malignant brain tumors, with complicated etiology and poor prognosis. However, there is still a lack of specific biomarkers for the diagnosis, treatment and prognosis assessment for glioma patients. Hence, the purpose of this study was to screen biomarkers for prognostic assessment and therapeutic interventions in gliomas.

MATERIAL AND METHODS

We utilized The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases to investigate the role of colony-stimulating factor 3 receptor (CSF3R) in glioma. Data analysis was conducted using R, GEPIA 2, TISCH and DepMap.

RESULTS

CSF3R was up-regulated in glioma and associated with the clinical pathological features of the patients. Kaplan-Meier survival analysis indicated a significant association between the expression of CSF3R and prognosis in patients. Univariate and multivariate Cox analyses revealed that patients with high expression of CSF3R have a worse prognosis, and the expression of CSF3R was an independent prognostic factor in gliomas. The nomogram constructed based on the expression of CSF3R demonstrated lower 1-, 3-, and 5-year overall survival (OS) in patients with high CSF3R expression. The biological functional analysis of CSF3R demonstrated its association with various immune regulatory signals. Furthermore, CSF3R was linked to the expression of immune checkpoints and resistance to immunotherapy. Notably, CSF3R was predominantly detected in monocytes/macrophages.

CONCLUSIONS

Our study suggested that CSF3R might potentially function as an independent prognostic factor for glioma and hold promise as a biomarker and target for immunotherapy in glioma.

摘要

引言

胶质瘤是最常见的恶性脑肿瘤，病因复杂，预后较差。然而，对于胶质瘤患者的诊断、治疗和预后评估，仍然缺乏特异性生物标志物。因此，本研究的目的是筛选用于胶质瘤预后评估和治疗干预的生物标志物。

材料与方法

我们利用癌症基因组图谱（TCGA）和中国胶质瘤基因组图谱（CGGA）数据库来研究集落刺激因子3受体（CSF3R）在胶质瘤中的作用。使用R、GEPIA 2、TISCH和DepMap进行数据分析。

结果

CSF3R在胶质瘤中上调，并与患者的临床病理特征相关。Kaplan-Meier生存分析表明CSF3R的表达与患者预后之间存在显著关联。单因素和多因素Cox分析显示，CSF3R高表达的患者预后较差，CSF3R的表达是胶质瘤的独立预后因素。基于CSF3R表达构建的列线图显示，CSF3R高表达患者的1年、3年和5年总生存率较低。CSF3R的生物学功能分析表明其与各种免疫调节信号相关。此外，CSF3R与免疫检查点的表达和免疫治疗耐药性有关。值得注意的是，CSF3R主要在单核细胞/巨噬细胞中检测到。

结论

我们的研究表明，CSF3R可能作为胶质瘤的独立预后因素，有望成为胶质瘤免疫治疗的生物标志物和靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/18aae1b26384/CEJI-49-54278-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/ecfa9c1570da/CEJI-49-54278-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/da3f8d32e4e9/CEJI-49-54278-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/2e49de4c149b/CEJI-49-54278-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/dfa1d1869634/CEJI-49-54278-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/c8e14d21b712/CEJI-49-54278-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/646b3fa4694e/CEJI-49-54278-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/18aae1b26384/CEJI-49-54278-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/ecfa9c1570da/CEJI-49-54278-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/da3f8d32e4e9/CEJI-49-54278-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/2e49de4c149b/CEJI-49-54278-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/dfa1d1869634/CEJI-49-54278-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/c8e14d21b712/CEJI-49-54278-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/646b3fa4694e/CEJI-49-54278-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d972/11457564/18aae1b26384/CEJI-49-54278-g007.jpg

相似文献

1
CSF3R as a potential prognostic biomarker and immunotherapy target in glioma.CSF3R作为胶质瘤潜在的预后生物标志物和免疫治疗靶点。
Cent Eur J Immunol. 2024;49(2):155-168. doi: 10.5114/ceji.2024.140651. Epub 2024 Jun 21.
2
MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.MCM10 作为一种新型的预后生物标志物及其与胶质瘤免疫浸润的相关性。
Technol Health Care. 2023;31(4):1301-1317. doi: 10.3233/THC-220576.
3
Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.胶质母细胞瘤预后生物标志物 SGSM1 及其与免疫浸润的相关性。
BMC Cancer. 2022 Apr 28;22(1):466. doi: 10.1186/s12885-022-09548-7.
4
Development and validation of a glioma prognostic model based on telomere-related genes and immune infiltration analysis.基于端粒相关基因和免疫浸润分析的胶质瘤预后模型的构建与验证
Transl Cancer Res. 2024 Jul 31;13(7):3182-3199. doi: 10.21037/tcr-23-2294. Epub 2024 Jul 22.
5
MELK is a prognostic biomarker and correlated with immune infiltration in glioma.MELK是一种预后生物标志物，与胶质瘤中的免疫浸润相关。
Front Neurol. 2022 Oct 24;13:977180. doi: 10.3389/fneur.2022.977180. eCollection 2022.
6
MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma.微小染色体维持蛋白4（MCM4）是一种新型的预后生物标志物，可促进胶质瘤中癌细胞的生长。
Front Oncol. 2022 Nov 17;12:1004324. doi: 10.3389/fonc.2022.1004324. eCollection 2022.
7
CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.CLCF1 是一种新型潜在的免疫相关靶点，对胶质瘤的预后和免疫治疗反应具有预测价值。
Front Immunol. 2022 Feb 21;13:810832. doi: 10.3389/fimmu.2022.810832. eCollection 2022.
8
CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.CKS2（CDC28 蛋白激酶调节亚基 2）是低级别胶质瘤的预后生物标志物：基于生物信息学分析和免疫组织化学的研究。
Bioengineered. 2021 Dec;12(1):5996-6009. doi: 10.1080/21655979.2021.1972197.
9
Integrated transcriptome, proteome and single-cell sequencing uncover the prognostic and immunological features of colony-stimulating factor 3 receptor in pan-cancer.整合转录组、蛋白质组和单细胞测序揭示了集落刺激因子 3 受体在泛癌中的预后和免疫特征。
J Gene Med. 2023 Oct;25(10):e3508. doi: 10.1002/jgm.3508. Epub 2023 Apr 27.
10
Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.基于抗肿瘤免疫的干扰素γ相关基因特征可预测胶质瘤患者的预后。
Front Genet. 2023 Jan 13;13:1053263. doi: 10.3389/fgene.2022.1053263. eCollection 2022.

引用本文的文献

1
Mechanistic Study of NT5E in Reg3β-Induced Macrophage Polarization and Cooperation with Plasma Proteins in Myocarditis Injury and Repair.NT5E在Reg3β诱导的巨噬细胞极化中的机制研究及其在心肌炎损伤与修复中与血浆蛋白的协同作用
Biology (Basel). 2025 Aug 7;14(8):1017. doi: 10.3390/biology14081017.

本文引用的文献

1
Lactate dehydrogenase A regulates tumor-macrophage symbiosis to promote glioblastoma progression.乳酸脱氢酶 A 调节肿瘤-巨噬细胞共生关系以促进神经胶质瘤进展。
Nat Commun. 2024 Mar 5;15(1):1987. doi: 10.1038/s41467-024-46193-z.
2
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory.TIM-3 阻断在弥漫性内在脑桥胶质瘤模型中促进肿瘤消退和抗肿瘤免疫记忆。
Cancer Cell. 2023 Nov 13;41(11):1911-1926.e8. doi: 10.1016/j.ccell.2023.09.001. Epub 2023 Oct 5.
3
PRMT6-CDC20 facilitates glioblastoma progression via the degradation of CDKN1B.
PRMT6-CDC20 通过降解 CDKN1B 促进胶质母细胞瘤进展。
Oncogene. 2023 Mar;42(14):1088-1100. doi: 10.1038/s41388-023-02624-7. Epub 2023 Feb 15.
4
Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment.胶质母细胞瘤的免疫检查点阻断：从肿瘤异质性到个体化治疗。
J Clin Invest. 2023 Jan 17;133(2):e163447. doi: 10.1172/JCI163447.
5
Microenvironment-driven metabolic adaptations guiding CD8 T cell anti-tumor immunity.微环境驱动的代谢适应指导CD8 T细胞抗肿瘤免疫。
Immunity. 2023 Jan 10;56(1):32-42. doi: 10.1016/j.immuni.2022.12.008.
6
Microglia and Brain Macrophages as Drivers of Glioma Progression.小胶质细胞和脑巨噬细胞作为胶质瘤进展的驱动因素。
Int J Mol Sci. 2022 Dec 9;23(24):15612. doi: 10.3390/ijms232415612.
7
Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions.神经胶质瘤的诊断和治疗：当前的挑战与基于纳米材料的解决方案。
J Control Release. 2022 Dec;352:338-370. doi: 10.1016/j.jconrel.2022.09.065. Epub 2022 Oct 27.
8
Predictive value of PIMREG in the prognosis and response to immune checkpoint blockade of glioma patients.PIMREG 在预测胶质瘤患者预后和免疫检查点阻断反应中的价值。
Front Immunol. 2022 Jul 15;13:946692. doi: 10.3389/fimmu.2022.946692. eCollection 2022.
9
Interrogating glioma-M2 macrophage interactions identifies Gal-9/Tim-3 as a viable target against -null glioblastoma.研究胶质瘤- M2 巨噬细胞相互作用发现 Gal-9/Tim-3 可作为 -null 型胶质母细胞瘤的潜在治疗靶点。
Sci Adv. 2022 Jul 8;8(27):eabl5165. doi: 10.1126/sciadv.abl5165.
10
Neuroplasticity of Glioma Patients: Brain Structure and Topological Network.胶质瘤患者的神经可塑性：脑结构与拓扑网络
Front Neurol. 2022 May 13;13:871613. doi: 10.3389/fneur.2022.871613. eCollection 2022.